Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) generates a wide range of news relevant to investors, health care professionals and industry observers. As a global, diversified pharmaceutical company with operations in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, its disclosures cover both business performance and strategic activity.
News updates commonly include financial results and segment performance, such as quarterly revenue trends across Salix, International, Solta Medical, Diversified Products and Bausch + Lomb. The company also releases information on capital structure actions, including exchange offers for senior secured notes and amendments to credit agreements at Bausch Health and Bausch + Lomb, which are detailed in press releases and Form 8-K filings.
Bausch Health’s news flow highlights business development and acquisitions, for example the acquisition of DURECT Corporation to expand its hepatology portfolio and the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. to strengthen Solta Medical’s distribution in China. Product and geographic expansion updates, such as OraPharma’s commercial expansion into Canada and Puerto Rico and regulatory milestones for aesthetic devices, also feature prominently.
In addition, the company announces conference participation and investor events, including presentations at healthcare conferences where management provides strategic and business updates and may discuss guidance ranges. For those tracking BHC, this news page offers a centralized view of official announcements on operations, financing, governance and growth initiatives. Investors and followers of the pharmaceutical and medical aesthetics sectors can review these items to understand how Bausch Health is executing on its stated priorities and managing its diversified portfolio.
Bausch Health (NYSE:BHC) and Solta Medical launched the Clear + Brilliant Touch laser in Canada following Health Canada approval on May 20, 2025. The dual-wavelength fractional laser expands Canadian access to customizable, low‑downtime skin resurfacing for multiple skin types and ages.
The System uses two handpieces (1440 nm and 1927 nm) with specific indications for wrinkles, dyschromia, pigmentation, texture and pore size, and is positioned as a year‑round, easy‑to‑use aesthetic option for physicians.
Bausch Health (NYSE:BHC) and OraPharma mark the 25th anniversary of ARESTIN (minocycline HCl) Microspheres, 1 mg, the only FDA‑approved locally applied antibiotic used adjunctively with scaling and root planing (SRP) for adult periodontitis. The product is supported by over two decades of clinical experience and recent commercial expansion into Canada and Puerto Rico.
The company emphasizes ongoing support for non‑surgical periodontal care and continued collaboration with the dental community.
Bausch Health (NYSE:BHC) reported Q4 2025 consolidated revenues of $2.80 billion (+9% reported, +6% organic) and full-year revenues of $10.27 billion (+7% reported, +5% organic). GAAP net loss for Q4 was $112 million; full-year GAAP net income was $157 million. Q4 adjusted EBITDA was $1.05 billion (up 13%); full-year adjusted EBITDA was $3.54 billion (up 7%). The company completed the China Solta acquisition, executed significant refinancing (including a $1.7B debt exchange) and provided 2026 guidance: revenues $10.625–$10.875B and adjusted EBITDA $3.875–$4.000B.
Bausch Health (NYSE:BHC) said Executive Vice President and CFO Jean-Jacques (JJ) Charhon and other management will attend the J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida, from March 2–4, 2026 to meet with investors. This is a management investor engagement announcement.
Bausch Health (NYSE: BHC) and its gastroenterology business Salix opened applications for the 2026 Salix Gastrointestinal Health Scholars Program. The program will award 10 scholarships of up to $10,000 to students living with GI disease for the 2026–2027 academic year. Applications close May 6, 2026, and recipients will be notified in summer 2026. Awards include undergraduate, graduate, and working/single-parent categories. Applicants must submit an online application, references, and an essay about their GI condition and a health care provider's role. More details and eligibility are available at the Salix scholarship webpage.
Bausch Health (NYSE:BHC) announced results from the global Phase 3 RED-C program studying amorphous-rifaximin SSD for primary prevention of hepatic encephalopathy in adults with liver cirrhosis on Jan 23, 2026.
The trials were safe and well-tolerated but did not meet the primary endpoint. Management said it is reviewing the full dataset to determine potential new development opportunities and thanked patients, investigators, and research teams. Bausch Health reaffirmed its commitment to hepatology and other therapeutic areas.
Bausch Health (NYSE: BHC) will release its fourth quarter and full year 2025 financial results after market close on Wednesday, February 18, 2026. The company will host a live conference call and webcast at 5:00 p.m. U.S. EST to discuss results and provide a business update. Presentation materials and a replay of the call will be made available on the company's Investor Relations website prior to and after the call.
Bausch Health (NYSE:BHC) announced that CEO Thomas J. Appio will participate at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026. Executive attendees include EVP/CFO Jean-Jacques Charhon and EVP/CMO & Head of R&D Jonathan Sadeh, M.D..
A live audio webcast will be accessible via the company's Investor Relations website at http://ir.bauschhealth.com/events-and-presentations, with a replay available after the event. Time: 3:45 p.m. PT / 6:45 p.m. ET.
Bausch Health (NYSE:BHC) announced final results and expiration of exchange offers for its outstanding 4.875% and 11.00% Senior Secured Notes due 2028. The offers expired on December 23, 2025. Holders validly tendered an aggregate of $2.7 billion of existing notes; the Offerors accepted existing notes resulting in approximately $1.6 billion principal amount of new 10.00% Senior Secured Notes due 2032, with settlement currently expected on December 26, 2025. The New Notes are unregistered in the U.S. and Canada and will be issued pursuant to the exchange terms described in the exchange offer memorandum.
Bausch Health (NYSE:BHC) announced early results of exchange offers to swap its outstanding 4.875% and 11.00% senior secured notes due 2028 for up to $1.6 billion aggregate principal of new 10.00% senior secured notes due 2032 issued by subsidiary 1261229 B.C. Ltd.
As of 5:00 p.m. ET on December 8, 2025, holders validly tendered $2,690,016,000 of existing notes, and the company expects to issue approximately $1,600 million of New Notes after applying the Maximum Notes Amount and proration. The Withdrawal Deadline passed on December 8; the Offers expire at 5:00 p.m. ET on December 23, 2025, with settlement expected within three business days after expiration.